fsd
fsd
gfd
gfd
Pipeline information
Our strategy is focused on five key pillars, incorporated in our culture and in our daily work.
AVT02
- Biosimilar candidate
- High-concentration adalimumab
- Reference biologic
- HUMIRA®
- Therapeutic area
- Immunology
Approved by
- CHMP
- Health Canada
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
*Licenced from Biosana
HUMIRA is registered trademark of AbbVie Inc.
STELARA and SIMPONI are registered trademarks of Janssen Biotech, Inc. XOLAIR is a registered trademark of Novartis AG
PROLINA and XGEVA are registered trademarks of Amgen, Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
Newsroom
Latest news
- Business16 May 2022
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
- Business11 May 2022
Alvotech and OACB Announce Extraordinary General Meeting to Approve Business Combination
- Business19 April 2022
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
- Business06 April 2022
Alvotech and STADA pave way to launching HUKYNDRA®(AVT02), a citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie
- Business08 March 2022
Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
- Business28 February 2022
FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®
- Business23 February 2022
Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan
- Business02 February 2022
Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
- Business18 January 2022
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
